Earnings Scorecard & Analyst Reports for NASDAQ:LTRN, NASDAQ:PSTX, NASDAQ:CWBR, NASDAQ:PTPI

0
53

LANTERN PHARMA (NASDAQ:LTRN) EARNINGS INFORMATION (NASDAQ:LTRN)

Lantern Pharma last posted its earnings data on March 10th, 2021. The reported ($0.47) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.47). Lantern Pharma has generated $0.00 earnings per share over the last year. Lantern Pharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, June 9th, 2021 based off prior year’s report dates.

IS LANTERN PHARMA A BUY RIGHT NOW? (NASDAQ:LTRN)

2 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Lantern Pharma in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” Lantern Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LTRN, but not buy additional shares or sell existing shares.
Lantern Pharma

POSEIDA THERAPEUTICS (NASDAQ:PSTX) EARNINGS INFORMATION (NASDAQ:PSTX)

Poseida Therapeutics last released its quarterly earnings results on March 11th, 2021. The reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.11. Poseida Therapeutics has generated ($6.86) earnings per share over the last year. Poseida Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, June 10th, 2021 based off prior year’s report dates.

IS POSEIDA THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:PSTX)

3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Poseida Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Poseida Therapeutics stock.
Poseida Therapeutics

COHBAR EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:CWBR)

IS COHBAR A BUY RIGHT NOW? (NASDAQ:CWBR)

4 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for CohBar in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” CohBar stock.
CohBar

PETROS PHARMACEUTICALS EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:PTPI)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN PETROS PHARMACEUTICALS? (NASDAQ:PTPI)

Wall Street analysts have given Petros Pharmaceuticals a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Petros Pharmaceuticals wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.